Sun Pharma Shuts Down Two Clinical Pharmacology Units In Vadodara
Signage is displayed at the Sun Pharmaceutical Industries Ltd. headquarters in Mumbai, India. (Photographer: Kanishka Sonthalia/Bloomberg)

Sun Pharma Shuts Down Two Clinical Pharmacology Units In Vadodara

Bookmark

Drug major Sun Pharmaceutical Industries Ltd. on Saturday said it is discontinuing operations at two clinical pharmacology units in Vadodara, Gujarat to bring in efficiencies in cost and processes.

"While we continue to make investments in our research and development operations, we also constantly evaluate our resources and future capacity requirements to bring in efficiencies in cost and processes," a Sun Pharma’s spokesperson said in a statement.

To ensure optimal utilisation of clinical pharmacology units that conduct bio-equivalence studies, the company is discontinuing operations at two centers at Tandalja and Akota in Vadodara, the spokesperson added.

"The bio-equivalence studies from these centers will be transferred to our other facilities. We are offering full support to the affected employees and helping them with out placement services," the spokesperson said.

As per industry sources, the move would impact around 80 staffers at the two locations. Sun Pharma has six major R&D centers at Vadodara, Mumbai, Gurgaon, Haifa (Israel), Brampton (Canada) and New Jersey (U.S.).

Also read: The Nexus Between Sun Pharma, Aditya Medisales And Dilip Shanghvi

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.